bioavailability enhancement

Bioavailability is the fraction of a swallowed dose that actually reaches the bloodstream intact and ready to work. Often that fraction is disappointingly small: the drug fails to dissolve, struggles to cross the gut wall, or gets chewed up by the liver on its first pass. Bioavailability enhancement gathers the strategies that plug these leaks so that more of each dose counts.

The leaks fall into a few categories, and the fixes target each. If the drug barely dissolves, solubility and dissolution tools help. If it dissolves but cannot cross the intestinal membrane, formulators may use permeation enhancers or design the molecule to be more permeable. If it is heavily destroyed by first-pass metabolism in the gut wall and liver, options include prodrugs that resist that metabolism, inhibitors of the degrading enzymes, or a different route of administration that bypasses the liver's first pass.

Each tactic has limits and risks. A permeation enhancer that loosens the gut barrier may let unwanted substances through too; inhibiting a metabolic enzyme to raise one drug's levels can dangerously raise the levels of other drugs the patient takes. And because bioavailability reflects several steps multiplied together, fixing the wrong bottleneck achieves nothing. Diagnosing which step actually limits a given drug is the essential first move.